Recent Articles
5 Mother’s Day Stocks for Many Happy Returns
May. 8, 2013, 9:00 am EDT – Spending on Mom is projected to rise to record levels this year -- these five companies are poised to gain from all that appreciation. More
Is $10,000 Gold Still a Possibility?
Apr. 18, 2013, 10:47 am EDT – A year after discussing the possibility of $10,000 gold, bullion expert Nick Barisheff still thinks that despite the metal's urgent decline, all the long-term drivers for a big push are still in place. More
First Solar’s Massive Surge Halts Trading
Apr. 9, 2013, 3:03 pm EDT – First Solar's bright 2013 outlook sparked a massive rally in late Tuesday trading that caused the Nasdaq to interrupt trading. More
Look Before You Leap With New Frontier ETFs
Apr. 3, 2013, 8:52 am EDT – Global X is offering funds with exposure to the hot markets of Nigeria and Central Asia / Mongolia. They're good options if you want to target those regions -- but you have to do your homework. More
50 Blue-Chip Stocks Increasing Dividends in Q1 2013
Mar. 29, 2013, 10:25 am EDT – What's not to love about a big, blue-chip stock that has put its money where its shareholders are with even bigger payouts? These 50 companies did just that in the first quarter of 2013. More
Biotech Movers: Peregrine, PharmAthene Climb on Analyst Coverage
Mar. 11, 2013, 8:30 am EDT – Last week in biotech news, Peregrine and PharmAthene both climbed on bullish analyst coverage. Also, find out why Sequenom shed double-digits in one day. More
Don’t Dismiss the Ol’ Diamonds
Mar. 6, 2013, 10:57 am EDT – Don't let your financial savvy blind you to the potential for big gains from the DIA exchange-traded fund. More
Biotech Movers: Affymax Crashes on Recall
Mar. 4, 2013, 8:40 am EDT – Last week, shares of Affymax got hammered when the company pulled back units of its sole commercial drug. Plus, find out what sent the biggest gainers skyward. More
Joe’s Jeans; Or, Why I Love Making Mistakes
Feb. 26, 2013, 8:00 am EDT – Everyone screws up sometimes. The least you can do is learn from the experience. More
Biotech Movers: Chelsea Doubles, Vivus Dips
Feb. 25, 2013, 9:15 am EDT – Last week, Vivus slipped on a rejection from European regulators. Plus, find out why Chelsea Therapeutics and Infinity Pharmaceuticals soared. More
